Clinical Profile and Outcomes in Brainstem Glioma: An Institutional Experience
Overview
Authors
Affiliations
Aim Of The Study: This study was to analyze the clinical outcomes of brain stem glioma treated with radiation therapy (RT) in our institution.
Material And Methods: Records of 48 patients with brainstem glioma treated between January 2007 and January 2013 were reviewed. Demographic variables, clinical variables, radiological findings and treatment details with respect to age, sex, location of tumor ( pontine Vs non pontine ), signs and symptoms, RT dose, follow up period and outcomes were recorded. Patients were subdivided into two groups based on their age, age <15 years (Group I) and age >=15 yrs (Group II).
Results: The median age at diagnosis was 10 years (range 4-50). Male to female ratio was 11:10. Of the 48 cases analyzed, 27 patients (56%) were in group I and 21 (44%) were in group II. Radiologically, 90.5% had involvement of pons. 10 (21%) patients received RT dose >60 Gy and 38 (79 %) patients received RT dose of 54-60 Gy. Median overall survival was 7months (range 3-44 months). Median overall survival in Group I and Group II was 4 months and 10 months respectively (P = 0.042).
Conclusions: Brain stem glioma in pediatric age group is associated with worse outcomes than in adults.
Pediatric Brainstem Gliomas: An Institutional Experience.
Ali Laghari A, Baig M, Bari E, Darbar A, Mushtaq N, Hani Abdullah U Asian J Neurosurg. 2020; 14(4):1144-1150.
PMID: 31903354 PMC: 6896630. DOI: 10.4103/ajns.AJNS_101_19.
Lei B, Huang Y, Zhou Z, Zhao Y, Thapa A, Li W J Cell Biochem. 2018; 120(4):6698-6708.
PMID: 30506951 PMC: 6587862. DOI: 10.1002/jcb.27966.
Brainstem glioma: Prediction of histopathologic grade based on conventional MR imaging.
Moharamzad Y, Taheri M, Niaghi F, Shobeiri E Neuroradiol J. 2017; 31(1):10-17.
PMID: 29148317 PMC: 5789999. DOI: 10.1177/1971400917743099.
Genetic and immune features of resectable malignant brainstem gliomas.
Zhang Y, Pan C, Wang J, Cao J, Liu Y, Wang Y Oncotarget. 2017; 8(47):82571-82582.
PMID: 29137285 PMC: 5669911. DOI: 10.18632/oncotarget.19653.